Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intratumoral in patients with treatment-refractory solid tumor malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01118819

Solid Tumor Malignancies

TERMINATED PHASE1

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

NCT00358397

Tumors

TERMINATED PHASE1

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

NCT02243917

Advanced Solid Tumors

TERMINATED PHASE1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

NCT04242199

Advanced Solid Tumor MSI-H/dMMR Tumors Cutaneous Squamous Cell Carcinoma +9 more

COMPLETED PHASE1

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

NCT06902350

Neoplasms Glioblastoma, Adult Small Cell Lung Carcinoma (SCLC)

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clostridium novyi-NT spores

Group Type EXPERIMENTAL

Clostridium novyi-NT spores

Intervention Type BIOLOGICAL

Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clostridium novyi-NT spores

Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

bacteria anaerobic bacteria

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of an advanced solid tumor malignancy. There must be a target tumor which is measureable, palpable or clearly identifiable under ultrasound or radiographic guidance and amenable to percutaneous injection of C. novyi-NT spores. The targeted lesion must have a longest diameter ≥ 1 cm and ≤ 12 cm and be measurable as defined by RECIST 1.1 criteria. The target lesion must not be located in either the thoracic, abdominal or pelvic cavities or in the brain. There must be no clinical, no functional, and no radiographic evidence of bone involvement at the site of the target lesion.
2. History of prior treatment with at least one line of systemic anticancer therapy, when an approved systemic therapy is available, and no curative option is available for continued treatment.
3. At least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
5. Patient is at least 18 years of age.
6. Patient is capable of giving informed consent.
7. Patient of childbearing potential (defined by the clinical sites' standards) is using adequate birth control measures (e.g., barrier method with spermicide; intrauterine device; implantable or injectable hormonal contraceptives; surgical sterilization) for the duration of the study and will continue to use such precautions for 12 months after receiving treatment.
8. Patient has no significant valvular heart disease (trace or mild valvular stenosis or regurgitation is allowed).
9. Patient is able to stay within 45 minutes driving time of an emergency room for 28 days after doing.
10. The patient has a caregiver for 28 days after dosing.

Exclusion Criteria

1. Positive pregnancy test.
2. Serum creatinine level \> 1.5 x the upper limit of normal (ULN), chronic renal failure requiring hemodialysis or peritoneal dialysis.
3. Patient has any of the following hematologic parameters:

* Platelet count equal to or less than 100,000/mm3
* Hemoglobin less than 9.0 g/dL
* Absolute neutrophil count (ANC) less than 1,000 /mm3
4. Oxygen saturation (Sp02) of less than 95% on room air.
5. Mean arterial blood pressure (BP) of less than 70 mmHg.
6. Glasgow Coma Score (GCS) of less than 15.
7. Treatment with an investigational drug within the past 30 days or 5 half-lives of that drug, whichever is shorter.
8. Documented primary brain malignancy or brain metastases.
9. Clinically significant ascites or clinical evidence or history of portosystemic hypertension or cirrhosis.
10. Laboratory evidence of hepatic dysfunction indicated by any of the following:

* Bilirubin ≥ 1.5 x the ULN
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 2.5X the ULN
* Alkaline phosphatase above 2.5X the ULN
* International normalized ratio (INR) greater than 1.3
11. Patient has a foreign body which in the opinion of the treating investigator could be difficult to manage in case of infection (e.g. prosthetic hip).
12. Clinically significant pleural effusion.
13. Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.
14. Need for ongoing treatment with an immunosuppressive agent.
15. History of solid organ transplantation (with the exception of a corneal transplant \> 3 months prior to screening).
16. History of an ischemic insult in the previous 12 months (myocardial infarction, cerebral vascular accident, ischemic tissue from injury, transient ischemic attack.
17. History of a significant medical illness deemed by the PI or local investigators as unsuitable for the trial. For example:

i. Symptomatic congestive heart failure ii. Psychiatric Illness/social situation that may make study dangerous iii. Unstable angina pectoris
18. Asplenia.
19. Antibiotic allergies that would preclude treatment for a C. novyi-NT infection.
20. Treatment with antibiotics within 2 weeks (14 days) of dosing.
21. Active and clinically significant systemic or localized infection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No